Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

International Journal of Cardiology

Volumn 212, Issue , 2016, Pages 203-205

  Kundu, Amartya ^a   Sardar, Partha ^b   Ghosh, Sreeparna ^c   Patel, Parth ^a   Chatterjee, Saurav ^d   Meyer, Theo E ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c INTERFAITH MEDICAL CENTER   (United States)

^d ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Alogliptin; Diabetes mellitus; Dipeptidyl peptidase 4 inhibitors; Heart failure; Saxagliptin; Sitagliptin

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN;

ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; AGED; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84962407615     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.03.016     Document Type: Article

References (10)

1. A. Dei Cas, S.S. Khan, J. Butler, and et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure JACC Heart Fail 3 2 2015 136 145
2. G.A. Nichols, C.M. Gullion, C.E. Koro, and et al. The incidence of congestive heart failure in type 2 diabetes: an update Diabetes Care 27 8 2004 1879 1884
3. J.J. McMurray, H.C. Gerstein, R.R. Holman, and M.A. Pfeffer Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored Lancet Diab Endocrinol 2 10 2014 843 851
4. J. Zhong, A. Goud, and S. Rajagopalan Glycemia lowering and risk for heart failure: recent evidence from studies of dipeptidyl peptidase inhibition Circ Heart Fail 8 4 2015 819 825
5. B.M. Scirica, D.L. Bhatt, E. Braunwald, and et al. SAVOR-TIMI 53 steering committee and investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 14 2013 1317 1326
6. F. Zannad, C.P. Cannon, W.C. Cushman, and et al. EXAMINE investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial Lancet 385 9982 2015 2067 2076
7. J.B. Green, M.A. Bethel, and P.W. Armstrong TECOS Study Group Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N Engl J Med 373 3 2015 232 242
8. S. Boudina, and E.D. Abel Diabetic cardiomyopathy revisited Circulation 115 25 2007 3213 3223
9. M. Monami, I. Dicembrini, and E. Mannucci Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials Nutr Metab Cardiovasc Dis 24 7 2014 689 697
10. S. Wu, I. Hopper, M. Skiba, and H. Krum Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants Cardiovasc Ther 32 4 2014 147 158